171 related articles for article (PubMed ID: 19709151)
1. An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.
Pratoomsoot C; Smith HT; Kalsekar A; Boye KS; Arellano J; Valentine WJ
Diabet Med; 2009 Aug; 26(8):803-14. PubMed ID: 19709151
[TBL] [Abstract][Full Text] [Related]
2. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia.
Reviriego J; Gomis R; Marañés JP; Ricart W; Hudson P; Sacristán JA
Int J Clin Pract; 2008 Jul; 62(7):1026-32. PubMed ID: 18489577
[TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
6. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.
Dunn CJ; Plosker GL
Pharmacoeconomics; 2002; 20(14):989-1025. PubMed ID: 12403639
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
8. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
9. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
Pollock RF; Curtis BH; Valentine WJ
J Med Econ; 2012; 15(4):766-75. PubMed ID: 22413830
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
Palmer JL; Knudsen MS; Aagren M; Thomsen TL
J Med Econ; 2010; 13(2):212-20. PubMed ID: 20350145
[TBL] [Abstract][Full Text] [Related]
11. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
Goodall G; Jendle JH; Valentine WJ; Munro V; Brandt AB; Ray JA; Roze S; Foos V; Palmer AJ
Int J Clin Pract; 2008 Jun; 62(6):869-76. PubMed ID: 18479280
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
13. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.
Palmer AJ; Valentine WJ; Ray JA; Foos V; Lurati F; Smith I; Lammert M; Roze S
Curr Med Res Opin; 2007 Apr; 23(4):895-901. PubMed ID: 17407646
[TBL] [Abstract][Full Text] [Related]
14. Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA
McEwan P; Bennett H; Bolin K; Evans M; Bergenheim K
Diabet Med; 2018 May; 35(5):557-566. PubMed ID: 29377320
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
16. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
17. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
18. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
Pollock RF; Curtis BH; Smith-Palmer J; Valentine WJ
Adv Ther; 2012 Dec; 29(12):1051-66. PubMed ID: 23179373
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
[TBL] [Abstract][Full Text] [Related]
20. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin.
Ferguson SC; Strachan MW; Janes JM; Frier BM
Diabetes Metab Res Rev; 2001; 17(4):285-91. PubMed ID: 11544612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
